A Randomized, Double-blind, Placebo-controlled Study of an RNAi-based Therapy Directed Against Respiratory Syncytial Virus

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2010 Apr 28

PMID 20421463

Citations 191

Authors

John DeVincenzo

Robert Lambkin-Williams

Tom Wilkinson

Jeffrey Cehelsky

Sara Nochur

Edward Walsh

Rachel Meyers

Jared Gollob

Akshay Vaishnaw

Affiliations

Soon will be listed here.

Abstract

RNA interference (RNAi) is a natural mechanism regulating protein expression that is mediated by small interfering RNAs (siRNA). Harnessing RNAi has potential to treat human disease; however, clinical evidence for the effectiveness of this therapeutic approach is lacking. ALN-RSV01 is an siRNA directed against the mRNA of the respiratory syncytial virus (RSV) nucleocapsid (N) protein and has substantial antiviral activity in a murine model of RSV infection. We tested the antiviral activity of ALN-RSV01 in adults experimentally infected with wild-type RSV. Eighty-eight healthy subjects were enrolled into a randomized, double-blind, placebo-controlled trial. A nasal spray of ALN-RSV01 or saline placebo was administered daily for 2 days before and for 3 days after RSV inoculation. RSV was measured serially in nasal washes using several different viral assays. Intranasal ALN-RSV01 was well tolerated, exhibiting a safety profile similar to saline placebo. The proportion of culture-defined RSV infections was 71.4 and 44.2% in placebo and ALN-RSV01 recipients, respectively (P = 0.009), representing a 38% decrease in the number of infected and a 95% increase in the number of uninfected subjects. The acquisition of infection over time was significantly lower in ALN-RSV01 recipients (P = 0.007 and P = 0.03, viral culture and PCR, respectively). Multiple logistic regression analysis showed that the ALN-RSV01 antiviral effect was independent of other factors, including preexisting RSV antibody and intranasal proinflammatory cytokine concentrations. ALN-RSV01 has significant antiviral activity against human RSV infection, thus establishing a unique proof-of-concept for an RNAi therapeutic in humans and providing the basis for further evaluation in naturally infected children and adults.

Citing Articles

Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses.

Luong Q, Hoang P, Ho P, Ayun R, Lee T, Lee S Int J Mol Sci. 2025; 26(4).

PMID: 40003946 PMC: 11855616. DOI: 10.3390/ijms26041481.

Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV.

Bowden-Reid E, Moles E, Kelleher A, Ahlenstiel C Drug Deliv Transl Res. 2025; .

PMID: 39833468 DOI: 10.1007/s13346-025-01788-x.

Therapeutic efficacy of JNJ-49214698, an RSV fusion inhibitor, in RSV-infected neonatal lambs.

Alnajjar S, Larios-Mora A, Van-Geelen A, Gallup J, Koul A, Rigaux P J Gen Virol. 2024; 105(12).

PMID: 39661432 PMC: 11634040. DOI: 10.1099/jgv.0.002056.

Virus-specific Dicer-substrate siRNA swarms inhibit SARS-CoV-2 infection in TMPRSS2-expressing Vero E6 cells.

Jiang M, Laine L, Kolehmainen P, Kakkola L, Avelin V, Vaisanen E Front Microbiol. 2024; 15:1432349.

PMID: 39611095 PMC: 11602746. DOI: 10.3389/fmicb.2024.1432349.

RNAi-Induced Gene Silencing against Chikungunya and COVID-19: What Have We Learned So Far, and What Is the Way Forward?.

Panda K, Alagarasu K, Tagore R, Paingankar M, Kumar S, Jeengar M Viruses. 2024; 16(9).

PMID: 39339965 PMC: 11437507. DOI: 10.3390/v16091489.

References

Buckingham S, Bush A, DeVincenzo J . Nasal quantity of respiratory syncytical virus correlates with disease severity in hospitalized infants. Pediatr Infect Dis J. 2000; 19(2):113-7. DOI: 10.1097/00006454-200002000-00006. View

Wianny F, Zernicka-Goetz M . Specific interference with gene function by double-stranded RNA in early mouse development. Nat Cell Biol. 2000; 2(2):70-5. DOI: 10.1038/35000016. View

Kleinman M, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi J . Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008; 452(7187):591-7. PMC: 2642938. DOI: 10.1038/nature06765. View

Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M . Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004; 432(7014):173-8. DOI: 10.1038/nature03121. View

Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411(6836):494-8. DOI: 10.1038/35078107. View

Harper S, Staber P, He X, Eliason S, Martins I, Mao Q . RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005; 102(16):5820-5. PMC: 556303. DOI: 10.1073/pnas.0501507102. View

Bitko V, Musiyenko A, Shulyayeva O, Barik S . Inhibition of respiratory viruses by nasally administered siRNA. Nat Med. 2004; 11(1):50-5. DOI: 10.1038/nm1164. View

Dykxhoorn D, Lieberman J . Knocking down disease with siRNAs. Cell. 2006; 126(2):231-5. PMC: 7125751. DOI: 10.1016/j.cell.2006.07.007. View

DeVincenzo J, Cehelsky J, Alvarez R, Elbashir S, Harborth J, Toudjarska I . Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008; 77(3):225-31. DOI: 10.1016/j.antiviral.2007.11.009. View

10.

Alvarez R, Elbashir S, Borland T, Toudjarska I, Hadwiger P, John M . RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother. 2009; 53(9):3952-62. PMC: 2737834. DOI: 10.1128/AAC.00014-09. View

11.

Feltes T, Sondheimer H . Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Expert Opin Biol Ther. 2007; 7(9):1471-80. DOI: 10.1517/14712598.7.9.1471. View

12.

Falsey A, Hennessey P, Formica M, Cox C, Walsh E . Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005; 352(17):1749-59. DOI: 10.1056/NEJMoa043951. View

13.

Lee F, Walsh E, Falsey A, Betts R, Treanor J . Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res. 2004; 63(3):191-6. DOI: 10.1016/j.antiviral.2004.04.005. View

14.

Thompson W, Shay D, Weintraub E, Brammer L, Cox N, Anderson L . Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003; 289(2):179-86. DOI: 10.1001/jama.289.2.179. View

15.

DeVincenzo J . Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr Res. 2004; 56(6):914-7. DOI: 10.1203/01.PDR.0000145255.86117.6A. View

16.

Martin J, Hamilton B, Sutton P, Ventura S, Menacker F, Kirmeyer S . Births: final data for 2005. Natl Vital Stat Rep. 2008; 56(6):1-103. View

17.

DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M . Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007; 104(43):17204-9. PMC: 2040405. DOI: 10.1073/pnas.0708285104. View

18.

Falsey A, Singh H, Walsh E . Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol. 2006; 78(11):1493-7. DOI: 10.1002/jmv.20724. View

19.

Morrissey D, Lockridge J, Shaw L, Blanchard K, Jensen K, Breen W . Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005; 23(8):1002-7. DOI: 10.1038/nbt1122. View

20.

Sheeran P, Jafri H, Carubelli C, Saavedra J, JOHNSON C, Krisher K . Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J. 1999; 18(2):115-22. DOI: 10.1097/00006454-199902000-00007. View